Become A Featured Company

A Look at the Company Behind Brazil’s CBD Reclassification & Legalization

Ryan Allway

July 19th, 2016

News, Top Story

In years past, most governments around the world would have been extremely skeptical about the medicinal properties of cannabis and cannabinoids, even as research was showing potential benefits across a wide range of indications.  Prior to the spring of 2014, Brazil was no exception with all cannabis-related products – including non-psychoactive components – considered illegal controlled substances.  But, these sentiments quickly changed thanks to a young Brazilian girl and some education regarding hemp-based cannabidiol (CBD).

Anny Fischer suffered from a rare form of genetic epilepsy called CDKL5, characterized by upwards of 300 seizure episodes per week. Desperate to alleviate the condition, her family read the Internet story of Harper Howard, posted by her parents on a blog called “Hope4Harper.”  Harper, a U.S. girl suffering from the same CDKL5 condition, found seizure relief using RSHO™ CBD oil.  The Brazilian federal health authority – ANVISA – granted the Fischer family the country’s first import authorization for RSHO™ while providing an historic ruling to remove non-psychoactive cannabidiol entirely from its list of prohibited substances.  The story is told on a documentary featured on YouTube titled: “Ilegal”: https://www.youtube.com/watch?v=CtJJ1pzMKxs.

Who is Behind RSHO™?

Medical Marijuana Inc. (OTC: MJNA) is the developer of Real Scientific Hemp Oil – or RSHO™ – billing it as the finest, most consistent, and 100% natural hemp CBD oil in the world. RSHO™ has been developed into a number of different formulations, including flavored drops, beauty creams for skincare, and even CanChew® gum, which is licensed to portfolio company Axim Biotechnologies (OTC: AXIM). These products are distributed through the company’s HempMeds division and Brazilian-approved RSHO™ products are distributed by its HempMeds Brasil™ subsidiary located in Brazil.

The Brazilian government decided to expand the indications allowed to then include Parkinson’s disease and chronic pain after securing the right to import RSHO™ as a prescription treatment for refractory epilepsy and seeing that their program was both well-received by families in Brazil and also able to be fully tracked by ANVISA. For those citizens who qualify for national healthcare coverage, their doctor-prescribed medications are covered by insurance.

Noting that no neurological condition has been effectively treated by pharmaceutical medicine, the regulatory authority has opened the doors for additional indications in the neurological category.

Available for import by doctor prescription, this additional list includes:

  • Alzheimer’s
  • Post Traumatic Stress (PTSD)
  • Attention Deficit Disorder (ADD / ADHD)
  • Multiple Sclerosis (MS)
  • Autism Spectrum Disorder

This latest government approval is significant because neurological disorders are on the rise throughout the world.  A recent article regarding the incidence of Parkinson’s disease and parkinsonism showed a significant increase within the past 30 years, according to the Mayo Clinic. Reported in JAMA Neurology, this is the first study to suggest such an increasing trend, particularly in men over age 70.

The numbers, for every ten calendar years of life:

  • Men of all ages have a 17% higher risk of developing “parkinsonism.
  • Men of all ages have a 24% higher risk of developing Parkinson’s disease.

Quantifying the Impact

Medical Marijuana, Inc. has generated revenue in excess of $1.5 million during each of its last four quarters leading up to March 31, 2016. While the company doesn’t break down revenue explicitly in its quarterly reports, it is likely that the majority of this revenue comes from the sale of its RSHO™ products. The additional indications in Brazil could open the door to wider sales in that country as it continues to market via HempMeds Brasil.

In addition, the ongoing approvals in Brazil could lead other Latin American countries to follow their lead in approving CBD products and allowing MJNA expanded access to emerging markets. Medical Marijuana, Inc. has already expanded its reach into Mexico, Paraguay, and other countries, and has begun to hire sales staff to further penetrate these markets. If the regulatory tide picks up, it could become a leading CBD supplier to all Latin American markets.

Finally, the move could open the door to further acceptance of RSHO™ and even medical cannabis in the larger U.S. market. Here, RSHO™ cannot make any claims in order to adhere to FDA guidelines. A recent Salk Institute study from San Diego referenced the fact that cannabis compounds can promote the removal of cellular beta amyloid proteins – toxins associated with Alzheimer’s. The study’s author, Dr. David Schubert, mentions: “although other studies have mentioned that cannabinoids might be neuroprotective against Alzheimer’s, we believe our study is the first to demonstrate that cannabinoids affect both inflammation and amyloid beta accumulation in nerve cells.”

Looking Ahead

Alzheimer’s affects 5.4 million Americans (link: http://www.alz.org/facts/) and well over 1 million in Brazil (http://www.alz.org/br/dementia-alzheimers-en.asp). In the US, the costs to Medicare in the care of these Alzheimer’s patients are expected to exceed $1 trillion by 2050. Link: https://www.washingtonpost.com/local/alzheimers-costs-could-soar-to-1-trillion-a-year-by-2050-report-says/2015/02/04/441bd16a-ac04-11e4-abe8-e1ef60ca26de_story.html

Currently there is no medication available to stop the progression of Alzheimer’s.

Medical Marijuana, Inc. has made tremendous progress in expanding the reach of its RSHO™ CBD hemp oil throughout Brazil and Latin America. The approval for numerous neurological indications in Brazil could significantly expand its addressable market, encourage other Latin American countries to follow suit, and potentially open the door to further acceptance in the U.S. over time – all positive factors to the company’s bottom line moving forward.

For more information, visit the company’s website at www.medicalmarijuanainc.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading